Board of Directors

Gisela Sitbon has a research background within molecular biology, combined with more than 25 years of senior level experience from the life science industry. This includes business development and operational positions, as well as co-founding and managing a service-providing diagnostic company, later acquired by Capio. Currently holds several chair positions and board appointments in private and stock market listed companies.

Born: 1958

Education: Doctor of Medical Sciences (PhD), Karolinska Institutet.

Previous experience: Board work in public, private and owner-managed companies. Sowing and growth financing in the Life Science sector. Entrepreneur, CEO and leading positions, such as business development, R&D and quality management systems, in innovative Life Science companies.

Other assignments: Gisela Sitbon is Chairman of the Board of
Emplicure Consumer AB, Emplicure AB, Emplicure Pharma AB and Nanologica
AB and Board member of UU Invest AB and Thioredoxin AB. In addition, she is
the owner and Board member of Sitbon Bioscience Partner ZENZ AB

Holding: 56,000 shares

Gisela Sitbon is independent in relation to the Company and the company management and the Company’s major shareholders, respectively.

Co-founder, owner and working chairman of the Swedish leading fund management firm Didner & Gerge. Other current commitments include the position as chairman for Uppsala University Invest and various board member positions. Henrik Didner holds a PhD in Business Administration from Uppsala University.

Born: 1958

Education: PhD, Uppsala University.

Previous experience: Fund management since 1994.

Other assignments: Henrik Didner is co-owner and Chairman of the Board of Didner & Gerge Fonder AB and Monesi Förvaltnings AB and Chairman of the Board of Uppsala universitet Invest AB. Henrik is also a Board member of G-Förvaltning AB, Oncodia AB, Axel Johansson Uppsala Nya Tidning Förvaltning AB, CLA Sweden AB, Baracken AB and VBN Components AB.

Holding: 7,056,198 shares (via Monesi Förvaltnings AB).

Henrik Didner is independent in relation to the company and the company management, but is not independent in relation to the company’s major shareholders.

Rolf Ehrnström has extensive R&D leadership experience from biotech and diagnostic companies like e.g. Amersham Pharmacia Biotech, Dako (acquired by Agilent) and the microfluidics pioneer company Gyros. Today, Rolf Ehrnström serves on the board of directors for various innovation-driven life science companies and is appointed independent partner at Ventac Partners.

Born: 1953

Education: Master of Science in Biochemistry and Biotechnology from KTH Stockholm.

Previous experience: 20 years in leading positions in R&D at Pharmacia Biotech, VP R&D at Gyros AB and CVP R&D at Dako A/S.

Other assignments: Rolf Ehrnström is Chairman of the Board and CEO of Reomics AB. Rolf is also a Board member of Scandinavian Chemotech AB, Fluimedix A/S, ZipPrime Oy, Aplex Bio AB and Lynsight Oy. In addition, he serves as a consultant within life science and is a member of various funding agencies (Vinnova, EITH, NOME and Uppsala Bio-X).

Holding:  18,659 shares (via Reomics AB)

Rolf Ehrnström is independent in relation to the company and the company management and the company’s major shareholders, respectively.

Hilja Ibert brings more than 30 years of experience from the clinical diagnostics industry at international companies like Hologic, Becton Dickinson and bioMérieux, including Vice President and General Manager positions within the business areas of Diagnostic systems and Bioscience. She is today chairperson, earlier CEO of the Norwegian listed company Gentian Diagnostics, and Board member of French VitaDX International.

Born: 1960

Education: PhD in Nutrition Science from the University of Bonn.

Previous experience: More than 30 years within the clinical diagnostics industry including CEO of miDiagnostics, VP/GM positions at Hologic and Becton Dickinson, Corporate Marketing Manager at bioMérieux, and most recently CEO of Gentian Diagnostics ASA.

Other assignments: Chairman of the Board of Gentian Diagnostics,
a Norwegian listed company with products in the international immunodiagnostic market. Hilja is also a Board member of VitaDx, a French company focusing on AI and image processing in the field of cancer cytology.

Holding:  –

Hilja Ibert is independent in relation to the company and the company management and the company’s major shareholders, respectively.

Nedal Safwat is an accomplished leader in the clinical diagnostic industry with 20+ years of global experience. Nedal Safwat has held diverse roles, gaining a comprehensive understanding of the industry. He has successfully led commercial teams, developing strategies for microbiology applications such as bacterial identification, antibiotic susceptibility testing, resistance, and sepsis detection.

Born: 1975

Education: Bachelor of Science and PhD in Biochemistry from North Carolina State University, USA.

Previous experience: VP Marketing and Business Development at Chromacode Inc, Executive Director, Director of Global Marketing and Director of Clinical Marketing at bioMérieux.

Other assignments: Nedal Safwat is Vice President Portfolio and Product Management Office at Cepheid, US.

Holding:  –

Nedal Safwat is independent in relation to the company and the company management and the company’s major shareholders, respectively.  

Veronica Byfield Sköld brings over 25 years of experience in international medtech and life sciences. She has held senior commercial roles at companies including Elekta and Permobil, and served as CEO of the biotech company BioLamina until 2024. Her previous experience also includes positions at Boston Consulting Group (BCG), Gambro, and as Partner at the private equity firm Impilo, where she currently remains on the Board. In addition, she serves on the Board of Dansens Hus, and holds an MSc in Industrial Engineering and Management from KTH Royal Institute of Technology.

Born: 1974

Education: MSc in Industrial Engineering and Management, KTH Royal Institute of Technology.

Previous experience: CEO for BioLamina AB, Senior Vice President Group Marketing & Medical Affairs at Permobil, Vice President Product & Service Commercialisation at Electa, Director Strategic Development at Gambro AB, Project Leader at Boston Consulting Group (BCG), and Partner at Impolio.

Other assignments: Veronica Byfield Sköld is Board member of Impolio and of Dansens Hus.

Holding:  –

Veronica Byfield Sköld is independent in relation to the company and the company management and the company’s major shareholders, respectively.

Jeffrey Schroder brings over two decades of experience guiding midsized manufacturing and distribution companies through sustained growth, operational transformation and strategic financial management. He currently serves as Vice President, Chief Financial Officer and Treasurer of Hardy Diagnostics, a medical device manufacturer and oversees Finance, Accounting, Human Resources and Plant Operations across multiple facilities in the United States.

Born: 1964

Education: Bachelor of Science in Accounting and Finance from Wright State University and a Master of Business Administration from the University of Dayton.

Previous experience: More than 20 years of experience from midsized manufacturing and distribution companies, including roles as Executive Vice President and Chief Financial Officer of Grey America, Controller at Chemineer, a division of NOV and Chief Financial Officer at Anchor Rubber.

Other assignments: Jeff is a member of the American Institute of Certified Public Accountants and the Ohio Society of Certified Public Accountants and he currently serves as Vice President, Chief Financial Officer and Treasurer of Hardy Diagnostics.

Holding:   –

Jeffrey Schroder is independent in relation to the company and the company management and the company’s major shareholders, respectively.